Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia : results from the 24-month follow-up of the BELA trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: 10.1111/bjh.13108
- Ereignis
-
Veröffentlichung
- (wo)
-
Aachen
- (wer)
-
Universitätsbibliothek der RWTH Aachen
- (wann)
-
2014
- Urheber
-
Brümmendorf, Tim Henrik
Cortes, Jorge E.
Souza, Cármino Antonio de
Guilhot, Francois
Duvillié, Ladan
Pavlov, Dmitri
Gogat, Karïn
Countouriotis, Athena M.
Gambacorti-Passerini, Carlo
- DOI
-
10.18154/RWTH-2015-05207
- URN
-
urn:nbn:de:101:1-2018110105503583310304
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brümmendorf, Tim Henrik
- Cortes, Jorge E.
- Souza, Cármino Antonio de
- Guilhot, Francois
- Duvillié, Ladan
- Pavlov, Dmitri
- Gogat, Karïn
- Countouriotis, Athena M.
- Gambacorti-Passerini, Carlo
- Universitätsbibliothek der RWTH Aachen
Entstanden
- 2014
Ähnliche Objekte (12)
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia : final results from the BFORE trial
Chronic Diarrhea Secondary to Newly Diagnosed VIPoma
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
The impact of newly diagnosed chronic paediatric conditions on parental quality of life
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Oral Health-Related Quality of Life in Adult Patients with Newly Diagnosed Acute Leukaemia
Spontaneous chest wall haematoma in chronic myeloid leukaemia
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia : final results from the BFORE trial
Chronic Diarrhea Secondary to Newly Diagnosed VIPoma
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
The impact of newly diagnosed chronic paediatric conditions on parental quality of life
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Oral Health-Related Quality of Life in Adult Patients with Newly Diagnosed Acute Leukaemia
Spontaneous chest wall haematoma in chronic myeloid leukaemia
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia : final results from the BFORE trial
Chronic Diarrhea Secondary to Newly Diagnosed VIPoma
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
The impact of newly diagnosed chronic paediatric conditions on parental quality of life
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Oral Health-Related Quality of Life in Adult Patients with Newly Diagnosed Acute Leukaemia